loading
Precedente Chiudi:
$1.29
Aprire:
$1.3
Volume 24 ore:
125.79K
Relative Volume:
0.17
Capitalizzazione di mercato:
$39.82M
Reddito:
-
Utile/perdita netta:
$-69.00M
Rapporto P/E:
-0.464
EPS:
-2.78
Flusso di cassa netto:
$-55.26M
1 W Prestazione:
-1.53%
1M Prestazione:
+11.21%
6M Prestazione:
-80.51%
1 anno Prestazione:
-78.99%
Intervallo 1D:
Value
$1.26
$1.33
Intervallo di 1 settimana:
Value
$1.15
$1.39
Portata 52W:
Value
$1.05
$10.16

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Name
Nome
Acrivon Therapeutics Inc
Name
Telefono
617-207-8979
Name
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Name
Dipendente
78
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-26
Name
Ultimi documenti SEC
Name
ACRV's Discussions on Twitter

Confronta ACRV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ACRV
Acrivon Therapeutics Inc
1.29 39.82M 0 -69.00M -55.26M -2.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-05 Ripresa Piper Sandler Overweight
2025-01-31 Iniziato KeyBanc Capital Markets Overweight
2024-09-16 Aggiornamento Ladenburg Thalmann Neutral → Buy
2024-04-29 Downgrade Ladenburg Thalmann Buy → Neutral
2024-03-01 Iniziato JMP Securities Mkt Outperform
2023-12-15 Ripresa Jefferies Buy
2023-10-05 Iniziato Maxim Group Buy
2023-06-02 Iniziato Oppenheimer Outperform
2023-05-08 Iniziato BMO Capital Markets Outperform
2023-04-27 Iniziato Ladenburg Thalmann Buy
2023-04-20 Iniziato H.C. Wainwright Buy
2022-12-12 Iniziato Cowen Outperform
2022-12-12 Iniziato Jefferies Buy
2022-12-12 Iniziato Piper Sandler Overweight
Mostra tutto

Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie

pulisher
Jun 13, 2025

Acrivon Therapeutics Holds Annual Stockholders Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 12, 2025

Analysts Offer Predictions for ACRV FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com

Jun 10, 2025
pulisher
Jun 07, 2025

Nuveen Asset Management LLC Sells 12,377 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World

Jun 07, 2025
pulisher
May 31, 2025

Northern Trust Corp Has $706,000 Stock Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World

May 31, 2025
pulisher
May 25, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of “Buy” from Analysts - Defense World

May 25, 2025
pulisher
May 21, 2025

Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating - TipRanks

May 21, 2025
pulisher
May 19, 2025

FY2025 EPS Estimate for Acrivon Therapeutics Cut by Analyst - Defense World

May 19, 2025
pulisher
May 19, 2025

Q3 EPS Forecast for Acrivon Therapeutics Boosted by Analyst - Defense World

May 19, 2025
pulisher
May 19, 2025

(ACRV) Investment Analysis and Advice - news.stocktradersdaily.com

May 19, 2025
pulisher
May 18, 2025

Jones Trading Reaffirms Hold Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World

May 18, 2025
pulisher
May 17, 2025

Acrivon Therapeutics (ACRV) Downgraded by Jones Trading | ACRV S - GuruFocus

May 17, 2025
pulisher
May 17, 2025

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch - Yahoo Finance

May 17, 2025
pulisher
May 17, 2025

Oppenheimer Issues Pessimistic Forecast for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World

May 17, 2025
pulisher
May 16, 2025

JonesResearch Downgrades Acrivon Therapeutics (ACRV) to Hold | ACRV Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 15, 2025

Acrivon Therapeutics (ACRV) Price Target Lowered by Oppenheimer - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Acrivon Therapeutics (ACRV) Price Target Lowered by Oppenheimer | ACRV Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Acrivon (ACRV) Advances Clinical Pipeline with Promising Data an - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Oppenheimer Cuts Price Target on Acrivon Therapeutics to $9 From $10, Keeps Outperform Rating - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating - TipRanks

May 15, 2025
pulisher
May 15, 2025

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock - Investing.com

May 15, 2025
pulisher
May 15, 2025

Acrivon Therapeutics (ACRV) Projects Funding Through Mid-2027 | - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Acrivon Therapeutics (ACRV) Price Target Reduced by Oppenheimer - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer - TipRanks

May 15, 2025
pulisher
May 15, 2025

Acrivon Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 15, 2025
pulisher
May 14, 2025

Acrivon Therapeutics (ACRV) Price Target Reduced by Oppenheimer | ACRV Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Acrivon Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

Acrivon Therapeutics Reports Positive ACR-368 Data for Endometrial Cancer and Appoints New Chief Medical Officer - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Resistant Endometrial Cancer Patients - Stock Titan

May 14, 2025
pulisher
May 11, 2025

Acrivon Therapeutics (ACRV) to Release Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 08, 2025

(ACRV) Investment Analysis - news.stocktradersdaily.com

May 08, 2025
pulisher
May 06, 2025

Acrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated by Analysts at Piper Sandler - Defense World

May 06, 2025
pulisher
May 05, 2025

Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research

May 05, 2025
pulisher
May 05, 2025

Piper Sandler Initiates Coverage on Acrivon Therapeutics (ACRV) with Overweight Rating | ACRV Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Piper Sandler sets $6 target for Acrivon stock, rates it Overweight - Investing.com Nigeria

May 05, 2025
pulisher
May 05, 2025

Piper Sandler sets $6 target for Acrivon stock, rates it Overweight By Investing.com - Investing.com South Africa

May 05, 2025
pulisher
May 05, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Sold by JPMorgan Chase & Co. - Defense World

May 05, 2025
pulisher
May 04, 2025

Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) PT at $21.80 - Defense World

May 04, 2025
pulisher
May 03, 2025

Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings - Defense World

May 03, 2025
pulisher
May 02, 2025

Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 19.9% - Defense World

May 02, 2025
pulisher
May 02, 2025

Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million By Investing.com - Investing.com Canada

May 02, 2025
pulisher
May 01, 2025

Major Shareholder Sells Massive Stake in Acrivon Therapeutics! - TipRanks

May 01, 2025
pulisher
May 01, 2025

Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million - Investing.com

May 01, 2025

Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Acrivon Therapeutics Inc Azioni (ACRV) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
PERCEPTIVE ADVISORS LLC
10% Owner
May 01 '25
Sale
1.34
298,886
400,507
3,104,139
PERCEPTIVE ADVISORS LLC
10% Owner
Apr 25 '25
Sale
1.95
1,054,669
2,056,605
4,306,189
PERCEPTIVE ADVISORS LLC
10% Owner
Apr 29 '25
Sale
1.41
250,000
352,500
3,840,906
PERCEPTIVE ADVISORS LLC
10% Owner
Apr 28 '25
Sale
1.56
215,283
335,841
4,090,906
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Capitalizzazione:     |  Volume (24 ore):